Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2014; 20(43): 16053-16061
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16053
Published online Nov 21, 2014. doi: 10.3748/wjg.v20.i43.16053
Management of chronic hepatitis B in severe liver disease
James Fung, Ching-Lung Lai, Man-Fung Yuen, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
Author contributions: Fung J, Lai CL and Yuen MF wrote the manuscript
Correspondence to: James Fung, Consultant, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. jfung@gastro.hk
Telephone: +852-22553830 Fax: +852-28162863
Received: March 17, 2014
Revised: April 22, 2014
Accepted: July 24, 2014
Published online: November 21, 2014
Processing time: 248 Days and 11.1 Hours
Revised: April 22, 2014
Accepted: July 24, 2014
Published online: November 21, 2014
Processing time: 248 Days and 11.1 Hours
Core Tip
Core tip: This review discusses the treatment of chronic hepatitis B in patients with underlying severe liver disease, including cirrhosis, acute on chronic liver failure, hepatocellular carcinoma, and those undergoing liver transplantation. Despite the availability of highly potent antiviral drugs, these patients are often difficult to manage. The use of currently available antiviral agents is discussed along with its efficacy in these patients with severe hepatitis B liver disease.